Potential Anti-Tumor Drug: Co-Crystal 5-Fluorouracil-nicotinamide | Zendy

Zhu-Yan Zhang | Zendy; Nan Yu | Zendy; Chang Xue | Zendy; Shan Gao | Zendy; ZhaoPeng Deng | Zendy; Min Li | Zendy; Cong Liu | Zendy; John J. Castellot | Zendy; Siying Han | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Potential Anti-Tumor Drug: Co-Crystal 5-Fluorouracil-nicotinamide

Author(s) -

Zhu-Yan Zhang,

Nan Yu,

Chang Xue,

Shan Gao,

ZhaoPeng Deng,

Min Li,

Cong Liu,

John J. Castellot,

Siying Han

Publication year - 2020

Publication title -

acs omega

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.779

H-Index - 40

ISSN - 2470-1343

DOI - 10.1021/acsomega.9b03574

Subject(s) - nicotinamide , partition coefficient , solubility , in vivo , solvent , chemistry , hydrogen bond , pharmacokinetics , crystal (programming language) , lead glass , materials science , chromatography , organic chemistry , pharmacology , molecule , medicine , microbiology and biotechnology , computer science , programming language , biology , enzyme

5-Fluorouracil-nicotinamide (5-FU-NCM), a co-crystal with a 2D layer structure formed by hydrogen bonds, was synthesized by solvent evaporation and liquid phase-assisted grinding at room temperature. Compared to 5-FU alone, the results of solubility, oil-water partition coefficient, anti-tumor effect in vivo and vitro, acute toxicity, and pharmacokinetic parameters indicate that the co-crystal is a potential anti-tumor drug.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research